INT331006

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.34
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 0.13
Pain Relevance 1.17

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (CYP2C9) oxidoreductase activity (CYP2C9) endoplasmic reticulum (CYP2C9)
CYP2C9 (Homo sapiens)
Pain Link Frequency Relevance Heat
Duloxetine 66 96.76 Very High Very High Very High
opioid receptor 2 83.04 Quite High
Serotonin 72 80.60 Quite High
Potency 6 77.56 Quite High
noradrenaline 50 75.56 Quite High
depression 82 63.08 Quite High
Nicotine 6 31.04 Quite Low
sSRI 82 27.36 Quite Low
withdrawal 6 24.04 Low Low
fluoxetine 46 22.28 Low Low
Disease Link Frequency Relevance Heat
Depression 96 63.08 Quite High
Reprotox - General 1 2 49.44 Quite Low
Reprotox - General 2 12 48.56 Quite Low
Vomiting 16 44.76 Quite Low
Overdose 4 25.08 Quite Low
Syndrome 4 20.48 Low Low
Dysesthesia 2 17.44 Low Low
Chills 2 16.16 Low Low
Sleep Disorders 8 15.84 Low Low
Heart Rate Under Development 8 6.84 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Extensive metabolism, predominantly via CYP1A2, to a lesser extent via CYP2D6, and at a very low rate via CYP2C9,151,152 has been reported, but the metabolites have no significant activity.153 Duloxetine is a moderate CYP2D6 inhibitor and may inhibit its own metabolism154,155 as well as the metabolism of CYP2D6 substrates, such as desimipramine.90,195 The inhibition or induction of CYP1A2 is not clinically important, and coadministration of duloxetine with CYP1A2 substrates does not necessitate their dose adjustment.193 However, potent inhibitors of CYP2D6 and CYP1A2 may result in enhanced duloxetine concentrations and a need for dose adjustment.191,193
Positive_regulation (at) of Localization (rate) of CYP2C9 associated with duloxetine
1) Confidence 0.34 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2938284 Disease Relevance 0.06 Pain Relevance 0.58
Extensive metabolism, predominantly via CYP1A2, to a lesser extent via CYP2D6, and at a very low rate via CYP2C9,151,152 has been reported, but the metabolites have no significant activity.153 Duloxetine is a moderate CYP2D6 inhibitor and may inhibit its own metabolism154,155 as well as the metabolism of CYP2D6 substrates, such as desimipramine.90,195 The inhibition or induction of CYP1A2 is not clinically important, and coadministration of duloxetine with CYP1A2 substrates does not necessitate their dose adjustment.193 However, potent inhibitors of CYP2D6 and CYP1A2 may result in enhanced duloxetine concentrations and a need for dose adjustment.191,193
Positive_regulation (via) of Localization (rate) of CYP2C9 associated with duloxetine
2) Confidence 0.34 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2938284 Disease Relevance 0.06 Pain Relevance 0.58

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox